

August 02, 2022

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended June 30, 2022

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended June 30, 2022 which were approved by the Board of Directors of the Company, at its meeting held on August 02, 2022 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 03:00 p.m. and concluded at 06:00 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited



Rajesh Shirambekar
Head – Legal & Company Secretary




Encl: as above

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of RPG Life Sciences Limited (the "Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The comparative Ind AS financial information of the Company for the corresponding quarter June 30, 2021 and March 31, 2022, included in these Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS financial statements of the Company for the year ended March 31, 2022, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on July 28, 2021 and April 29, 2022 respectively.

For SRBC & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003


per Aruna Kumaraswamy
Partner
Membership No.: 219350



UDIN: 22219350AOAXRH1450

Place: Mumbai
Date: August 02, 2022

Statement of Financial Results for the quarter ended 30th June 2022

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
1 Revenue from Operations	12,893	10,380	10,813	44,016
2 Other Income	122	126	41	299
3 Total Income	13,015	10,506	10,854	44,315
4 Expenses				
(a) Cost of Materials Consumed	2,126	2,301	2,087	8,813
(b) Purchases of Stock-in-Trade	2,012	1,659	1,484	7,890
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	216	(339)	(76)	(2,521)
(d) Employee Benefits Expense	2,708	2,504	2,360	9,997
(e) Finance Costs	11	6	13	52
(f) Depreciation and Amortisation Expense	383	378	396	1,566
(g) Other Expenses	3,047	2,904	2,663	11,201
Total Expenses	10,503	9,413	8,927	36,998
5 Profit before tax (3-4)	2,512	1,093	1,927	7,317
6 Income tax expenses				
a. Current Tax	658	410	578	2,276
b. Deferred Tax	33	(69)	(9)	(107)
7 Profit for the period (5-6)	1,821	752	1,358	5,148
8 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(9)	(24)	(4)	(36)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	8	1	11
Other Comprehensive Income Net of Tax	(7)	(16)	(3)	(25)
9 Total Comprehensive Income for the period (7+8)	1,814	736	1,355	5,123
10 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
11 Other Equity				24,254
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic	11.01	4.55	8.21	31.13
(b) Diluted	11.01	4.55	8.21	31.13


Notes:

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on August 02, 2022.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- The figures of the quarter ended 31 March, 2022 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures upto 31 December, 2021, which were subjected to limited review.
- The Company exercised the option of lower tax rate under section 115 BAA of Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 effective April 01, 2022. Accordingly, the Company has adopted the new tax rate of 25.17% which has resulted in a reversal of deferred tax balances of Rs 46 lakhs on account of remeasurement of deferred tax balances as at 31st March, 2022 and is recognised in the financial results for the period ended 30th June, 2022
- Previous period's figures have been regrouped/reclassified wherever necessary.

SIGNED FOR IDENTIFICATION
 BY

 SRBC & CO LLP
 MUMBAI

For RPG Life Sciences Limited


 Yugal Sikri
 Managing Director
 Mumbai, August 02, 2022

